Table 2.
Subgroups analysis.
| Subgroup | n | WMD of BMI (95% CI) | Test for heterogeneity | Significance test |
|---|---|---|---|---|
| Baseline BMI | ||||
| Overweight (25–29.9 kg/m²) | 325 | −0.97 (–1.31, –0.63) | I²=0.0%, p = 0.764 | z=5.58; p = 0.000 |
| Class I obesity (30–34.9 kg/m²) | 272 | −0.99 (–1.48, –0.50) | I²=0.0%, p = 0.993 | z = 3.96; p = 0.000 |
| class II/III obesity (>35 kg/m²) | 407 | −1.12 (–1.84, –0.39) | I²=0.0%, p = 0.917 | z = 3.02; p = 0.002 |
| Mean age (years) | ||||
| 7–19 | 406 | −0.84 (–1.52, –0.16) | I² = 0.0%, p = 0.988 | z = 2.41; p = 0.016 |
| 19–39 | 183 | −1.01 (–2.00, –0.01) | I² = 0.0%, p = 0.981 | z = 1.98; p = 0.048 |
| 39–65 | 415 | −1.02 (–1.13, –0.73) | I² = 0.0%, p = 0.643 | z = 6.80; p = 0.000 |
| Metformin dose (mg/d) | ||||
| Low (⩽1500) | 321 | −0.88 (–1.63, –0.14) | I² = 0.0%, p = 0.966 | z = 2.34; p = 0.019 |
| High (>1500) | 683 | −1.01 (–1.29, –0.73) | I² = 0.0%, p = 0.986 | z = 7.10; p = 0.000 |
| Treatment length (months) | ||||
| <6 | 333 | −0.98 (–1.27, –0.69) | I² = 0.0%, p = 0.988 | z = 6.53; p = 0.000 |
| 6 | 500 | −1.09 (–1.71, –0.47) | I² = 0.0%, p = 0.882 | z = 3.44; p = 0.001 |
| >6 | 171 | −0.78 (–2.08, 0.52) | I² = 0.0%, p = 0.984 | z = 1.18; p = 0.238 |
BMI, body mass index; CI, confidence interval; WMD, weighted mean difference (used for the study of continuous variables with the same unit of measurement in meta-analysis).